NCT02564198

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 12 Months – 21 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Conditions

• Pediatric Solid Tumor
• Refractory Tumor
• Recurrent Tumor
• CNS Malignancies

Interventions

Type	Name	Description
DRUG	Ramucirumab	Administered IV

Timeline

• Start date: 2015-12-11
• Primary completion: 2019-07-16
• Completion: 2019-07-16
• First posted: 2015-09-30
• Last updated: 2021-08-17
• Results posted: 2021-08-17

Locations

21 sites across 1 country: United States